Clinical Trial Search

Primary: Visual Acuity Change From Baseline to Month 12 of the Study — 0.1; -0.05 LogMAR Unit

Primary: Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Mean Score — 58; 4 Percentage change in PASI mean score

Primary: Pathologic Complete Response Rate — 8.7; 0.0; 4.3; 0.0 percentage of participants

Primary: Insulin Sensitivity — 3.4; 2.7; 3.2; 3.0 min-1/pmol/mlx10-5 — p=0.55

Primary: Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status — 49; 21; 70; 1 number of participants

Primary: Number of Healthy Participants Negative for Reaction at 24 Hours After Intradermal Injection With ESAT6-CFP10 — 13; 13; 14; 13 participants

Primary: Increase in Dystrophin Expression in the Muscle Biopsies by Immunofluorescence Analyses of Cross-sections and by Western Blot Analyses of Total Protein Extracts — 1; 1…

Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Primary: Change From Baseline in 24 h UGE (g/24 h) After Seven Days of Treatment With Empagliflozin 2.5 mg, 10 mg, or 25 mg, or Placebo — -3.56; 72.45; 103.33; 101.79 g/24h…

Primary: To Assess the Potential Efficacy of Anakinra in Improving Hearing Thresholds in Corticosteroid-resistant Patients With Autoimmune Inner Ear Disease — 7 responders

Primary: PSA Slope (Trajectory) or the Change in PSA Level Over Time — 0.59; 0.27 ng/mL

Primary: Change in GFR From Baseline to 12 Months — 72.8; 70.3; 73.1; 74.4 ml/min/1.73m^2 — p=<0.01

Primary: Response Rate — 0; 0; 1; 0 participants

Primary: Investigator-assessed Progression-Free Survival (PFS) — 9.4; 10.7 months — p=0.706

Primary: Optimal Bendamustine Dosage for Further Studies — 60 mg/m^2